Oral News and Research

RSS

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

$7.2 million grant awarded to develop microbicide-releasing vaginal ring

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a four-year, $7.2 million grant to develop a microbicide-releasing vaginal ring to prevent HIV transmission.

3 Oct 2009

Array BioPharma to present poster on ARRY-403 glucokinase activator

Array BioPharma Inc. today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

2 Oct 2009

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

AFRESA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, according to data presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes.

2 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

TriPollar technology effective in reducing stretch marks

Dr. Worophong Manuskiatti has been invited to present results of his study "Treatment of striae distensae in skin phototypes IV-V with a TriPollar radiofrequency device" in the upcoming meeting of the European Academy of Dermatology and Venereology (EADV) Conference held on October 7-10, 2009 in Berlin, Germany.

1 Oct 2009

Individuals invited to participate in National Board written exam pilot

The National Board of Certification for Medical Interpreters continues to advance towards the launch of a single national certification process that will award individuals the credential of "Certified Medical Interpreter" (CMI) in a specific language. It recently concluded the pilot of the National Board oral exam and commenced the pilot of the National Board written exam with an open call to the field for participants.

1 Oct 2009

Most American children don't see their family dentist until they are 2 years old, reveals survey

Most American children don't see their family dentist until they are well over 2 years old, far later than is recommended by both dental and medical professionals.

1 Oct 2009

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Cell Therapeutics, Inc. announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.

1 Oct 2009

Treatment of gestational diabetes benefits both infant and mother

A National Institutes of Health network study provided the first conclusive evidence that treating pregnant women who have even the mildest form of gestational diabetes can reduce the risk of common birth complications among infants, as well as blood pressure disorders among mothers.

1 Oct 2009

Study reveals that training pediatricians will help reduce early childhood cavities

Researchers at Boston University School of Medicine (BUSM) have found that pediatricians provided with the proper communication, educational and information technology tools and training could reduce the rates of children developing early childhood caries (ECC) or cavities by 77 percent. This study appears in the October issue of the Journal Medical Care.

1 Oct 2009

Annual campaign to help patients learn about, manage and prevent diabetes

Rite Aid has kicked off its annual campaign on diabetes management by supporting the American Diabetes Association, the leading diabetes voluntary health organization, and dLife, the leading online diabetes resource, in the fight to stop diabetes.

1 Oct 2009

EMD Serono submits NDA for Cladribine Tablets in the U.S.

EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

Lumenis to discuss different treatment options for laryngeal cancer at 2009 AAO-HNS

Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.

From Lumenis Inc. 30 Sep 2009

Non-human primate study results of Restanza released

Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Ontario's doctors to stress the importance of health care professionals working together to the Standing Committee

At an appearance today before the Ontario Legislative Standing Committee on Social Policy, Ontario's doctors will stress the importance of health care professionals working together to enhance and strengthen the delivery of safe and quality care to patients.

30 Sep 2009

New anticoagulant therapy has fewer side-effects than warfarin

In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.

30 Sep 2009

Also in global health news: Drought in East Africa; improving food processing in Africa; Hajj pilgrims must take polio vaccine; fighting insecticide-resistant mosquitoes

"A severe and persistent five-year drought" is pushing "[m]ore than 23 million people ... towards severe hunger and destitution across East Africa, international aid agency Oxfam has warned as it launches a £9.5 million [about $15 million] emergency appeal," the U.K. Press Association reports (9/29). According to Reuters/New York Times, "Malnutrition is now above emergency levels in some areas and hundreds of thousands of valuable cattle are dying" (Wallis, 9/29).

30 Sep 2009

Oral News and Research

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

$7.2 million grant awarded to develop microbicide-releasing vaginal ring

Array BioPharma to present poster on ARRY-403 glucokinase activator

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

HRA Pharma launches its new generation emergency contraceptive in Europe

TriPollar technology effective in reducing stretch marks

Individuals invited to participate in National Board written exam pilot

Most American children don't see their family dentist until they are 2 years old, reveals survey

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Treatment of gestational diabetes benefits both infant and mother

Study reveals that training pediatricians will help reduce early childhood cavities

Annual campaign to help patients learn about, manage and prevent diabetes

EMD Serono submits NDA for Cladribine Tablets in the U.S.

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Lumenis to discuss different treatment options for laryngeal cancer at 2009 AAO-HNS

Non-human primate study results of Restanza released

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Ontario's doctors to stress the importance of health care professionals working together to the Standing Committee

New anticoagulant therapy has fewer side-effects than warfarin

Also in global health news: Drought in East Africa; improving food processing in Africa; Hajj pilgrims must take polio vaccine; fighting insecticide-resistant mosquitoes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News